

Special Issue

Novel Therapies and Biomarkers for Celiac Disease and Gluten-Related Disorders

Message from the Guest Editor

Celiac Disease (CD) and the other gluten-related disorders (GRDs) are epidemiologically relevant phenomena with an approximate global prevalence near to 5%, involving different systems and metabolic pathways. Various mechanisms, both autoimmune and inflammatory, are implicated in the pathogenesis of GRDs and frequently share similar clinical manifestations, making their differential diagnosis challenging. They could involve different parts of the gastrointestinal tract, skin, and nervous and musculoskeletal systems, as they are systemic disorders. Among GRDs, CD is the most well-known, prevalent, and commonly studied. In this Special Issue, we aim to expand our knowledge on all of the fundamental aspects of CD and other GRDs; therefore, this Special Issue will include new studies concerning the biological effect of gluten and new molecules as candidates for use in therapies, as novel therapeutic targets, biomarkers to diagnose GRDs and in monitoring the clinical responsiveness and, in general, new insights in the pathogenesis of GRD.

Guest Editor

Dr. Luca Elli

Center for Prevention and Diagnosis of Coeliac Disease-
Gastroenterology and Endoscopy Unit, Fondazione IRCCS Ca' Granda
Ospedale Maggiore Policlinico, Via F. Sforza 35, 20122 Milan, Italy

Deadline for manuscript submissions

closed (30 September 2022)



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



mdpi.com/si/118480

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).